<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for advanced esophagogastric adenocarcinoma: Ramucirumab plus weekly paclitaxel&lt;SUP&gt;[1]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for advanced esophagogastric adenocarcinoma: Ramucirumab plus weekly paclitaxel<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for advanced esophagogastric adenocarcinoma: Ramucirumab plus weekly paclitaxel<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 28 days.<br/> <strong>Duration of therapy:</strong> Treatment is continued until disease progression, unacceptable toxicity, or patient withdrawal. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Ramucirumab</td> <td>8 mg/kg IV</td> <td>Dilute with NS to a total volume of 250 mL.*<sup>¶</sup> The first dose should be administered over 60 minutes. If tolerated, subsequent infusions may be administered over 30 <span style="white-space: nowrap;">minutes.<sup>[2]</sup></span> Administer prior to paclitaxel on days both agents are administered.</td> <td>Days 1 and 15</td> </tr> <tr class="divider_bottom"> <td>Paclitaxel</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS* (final concentration of 0.3 to 1.2 mg/mL) and administer over 60 minutes.<sup>Δ</sup></td> <td>Days 1, 8, and 15</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>LOW (10 to 30%).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Premedication with a glucocorticoid and H1 and H2 receptor blockers is standard for paclitaxel. Patients who receive weekly paclitaxel have the potential to receive substantial doses of dexamethasone; ongoing glucocorticoid treatment is unnecessary in most. One option is to administer a lower dexamethasone dose (10 mg IV) with an H1 and H2 receptor blocker 30 minutes prior to the first administration. Glucocorticoid doses can then be tapered by weekly 2-mg decrements in patients without infusion reactions, and eventually <span style="white-space: nowrap;">discontinued.<sup>[3,4]</sup></span></li> <li>For ramucirumab, premedication with an IV H1 receptor antagonist is recommended prior to each <span style="white-space: nowrap;">infusion.<sup>[2]</sup></span> For patients who have experienced a grade 1 or 2 infusion-related reaction, premedicate with an H1 receptor antagonist, dexamethasone (or equivalent), and acetaminophen prior to each subsequent <span style="white-space: nowrap;">infusion.<sup>[2]</sup></span></li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy and infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Paclitaxel can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or kidney dysfunction</strong></td> <td colspan="3"> <ul> <li>Ramucirumab does not require dose adjustments for liver or renal dysfunction. However, patients with pre-existing Child-Pugh B or C liver dysfunction may have new-onset or worsening encephalopathy, ascites, or hepatorenal syndrome during treatment with ramucirumab. Use in patients with Child-Pugh B or C cirrhosis only if the potential benefits of treatment are judged to outweigh the risks of clinical <span style="white-space: nowrap;">deterioration.<sup>[2]</sup></span></li> <li>A lower starting dose of paclitaxel may be needed in patients with liver impairment.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Cardiovascular issues</strong></td> <td colspan="3"> <ul> <li>Control hypertension prior to initiating treatment.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for signs/symptoms of infusion reaction.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential weekly during treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Serum electrolytes and liver and renal function tests prior to each new treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Prior to each treatment, assess changes in blood pressure, neurologic symptoms/function, signs of GI perforation, and risk for bleeding and/or blood clots. Periodically assess urine protein concentration by dipstick and/or routine urinalysis.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor thyroid function during treatment.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Infusion related reaction</strong></td> <td colspan="3"> <ul> <li>For both ramucirumab and paclitaxel: <ul> <li>Manage symptoms per institutional standards.</li> <li>Reduce the infusion rate by 50% for grade 1 to 2 <span style="white-space: nowrap;">reactions.<sup>[2]</sup></span></li> <li>Permanently discontinue for grade 3 to 4 <span style="white-space: nowrap;">reactions.<sup>[2]</sup></span></li> </ul> </li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy and infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Initiation of each cycle (day 1) should be delayed until ANC is &gt;1500/microL and the platelet count is <span style="white-space: nowrap;">&gt;100,000/microL.<sup>[1]</sup></span></li> <li>Day 8 and 15 paclitaxel should be held until ANC is &gt;1000/microL and the platelet count is <span style="white-space: nowrap;">&gt;75,000/microL.<sup>[1,5]</sup></span></li> <li>For patients who develop grade 4 hematologic toxicity, the dose of paclitaxel should be reduced by 10 mg/m<sup>2</sup> for subsequent <span style="white-space: nowrap;">courses.<sup>[1]</sup></span></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiovascular toxicity</strong></td> <td colspan="3"> <ul> <li>Withhold ramucirumab for severe hypertension until medically controlled. Dose adjustment may be needed for grade 2 or greater <span style="white-space: nowrap;">hypertension.<sup>[1]</sup></span></li> <li>Permanently discontinue for medically significant hypertension that cannot be controlled with antihypertensive therapy or in patients with hypertensive crisis or hypertensive encephalopathy.</li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, cardiovascular effects.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hepatotoxicity</strong></td> <td colspan="3"> <ul> <li>Do not administer treatment on any day if total bilirubin is &gt;1.5 × ULN, and AST/ALT is &gt;3 × ULN (if no liver metastases), or &gt;5 × ULN (if liver <span style="white-space: nowrap;">metastases).<sup>[1]</sup></span></li> <li>Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each <span style="white-space: nowrap;">cycle.<sup>[5]</sup></span> However, none of the data used to derive these guidelines were from patients treated with weekly paclitaxel, and it is unknown if these dose reduction schemata are suitable for such patients.</li> <li>Discontinue ramucirumab for new occurrence of hepatic encephalopathy or hepatorenal <span style="white-space: nowrap;">syndrome.<sup>[1]</sup></span></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Wound healing</strong></td> <td colspan="3"> <ul> <li>Withhold ramucirumab for 28 days prior to elective surgery.</li> <li>Do not administer ramucirumab for at least 28 days following a major surgical procedure and until the wound is fully healed.</li> <li>Discontinue ramucirumab in patients who develop wound healing complications that require medical intervention.</li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, non-cardiovascular effects.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurotoxicity</strong></td> <td colspan="3"> <ul> <li>For patients who develop severe peripheral neuropathy (≥grade 2) for a week or longer, the dose of paclitaxel should be reduced by 10 mg/m<sup>2</sup> for subsequent <span style="white-space: nowrap;">courses.<sup>[1]</sup></span></li> <li>Refer to UpToDate topics on overview of neurologic complications of conventional non-platinum cancer chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Proteinuria</strong></td> <td colspan="3"> <ul> <li>For urine dipstick protein 2+ or greater, hold ramucirumab and perform a 24-hour urine collection for protein measurement. Withhold ramucirumab for urine protein ≥2 g over 24 hours. Reinitiate therapy at reduced <span style="white-space: nowrap;">dose<sup>[2]</sup></span> once urine protein level returns to &lt;2 g over 24 hours. Permanently discontinue in the setting of nephrotic syndrome.</li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, non-cardiovascular effects.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other toxicity</strong></td> <td colspan="3"> <ul> <li>Reduce paclitaxel dose by 10 mg/m<sup>2</sup> for all subsequent doses for grade 3 nonhematologic toxicity (expect alopecia) attributed to <span style="white-space: nowrap;">paclitaxel.<sup>[1]</sup></span></li> <li>Discontinue ramucirumab for serious hemorrhage, arterial thromboembolism, nephrotic syndrome, grade 3 or worse heart failure, GI perforation, or RPLS, or any other grade 4 (life-threatening) nonhematologic toxicity thought related to <span style="white-space: nowrap;">ramucirumab.<sup>[1,2]</sup></span></li> <li>Discontinue ramucirumab for a grade 3 or 4 venous thromboembolic event that is considered to be life threatening or that cannot be adequately treated with low-molecular-weight hepatin-based therapy, or that developed during anticoagulant <span style="white-space: nowrap;">therapy.<sup>[1]</sup></span></li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, non-cardiovascular effects and toxicity of molecularly targeted antiangiogenic agents, cardiovascular effects.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; CBC: complete blood count; GI: gastrointestinal; ANC: absolute neutrophil count; ULN: upper limit of normal; AST: aspartate transaminase; ALT: alanine aminotransferase; RPLS: reversible posterior leukoencephalopathy syndrome; D5W: 5% dextrose in water.<br/>* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Ramucirumab is incompatible with dextrose containing solutions.<sup>[2]</sup><br/>¶ Infuse through a separate infusion line using an infusion pump; the use of an 0.22-micron protein-sparing filter is recommended. Do not administer as an IV push or bolus. Flush the line with NS* after infusion is complete. Do not infuse in the same IV line with solutions other than NS*, or with electrolytes or other medications.<br/>Δ Paclitaxel can be administered in NS, D5W, or NS/D5W* at varying concentrations between 0.3 and 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<sup>[5]</sup></div><div class="graphic_reference">References: 

<ol>
<li>Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15:1224.</li>
<li>Ramucirumab. United States Prescribing Information. US National Library of Medicine. Available at: <a href="https://www.dailymed.nlm.nih.gov" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf</a> (Accessed on August 20, 2021).</li>
<li>Berger MJ, Vargo C, Vincent M, et al. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2015; 23:2019.</li>
<li>Parinyanitikul N, Tanpipattanakul W, Poovorawan N, et al. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. Support Care Cancer 2018; 26:2471.</li>
<li>Paclitaxel. United States Prescribing Information. US National Library of Medicine. Available at: <a href="https://www.dailymed.nlm.nih.gov" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf</a> (Accessed on August 20, 2021).</li></ol></div><div id="graphicVersion">Graphic 132475 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
